Day: June 25, 2024

First Commercial Agreement for DispersinB® WINNIPEG, Manitoba, June 25, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech” or “Kane”) announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB® technology. Biofilm is a known contributor to Meibomian gland dysfunction (MGD) and dry eye blepharitis syndrome (DEBS). The DispersinB® enzyme will be used to enhance I-MED’s line of eye care products. The license agreement covers a period of five years and includes minimum annual royalties, which will start in 2025. “This agreement is significant for Kane as it represents the first commercial agreement for DispersinB®,” said Marc Edwards, President & CEO. “We are delighted to partner with I-MED in providing DispersinB® biofilm...

CEOs of both companiesCEOs of both companiesTOKYO, Japan, June 25, 2024 (GLOBE NEWSWIRE) — Lead Real Estate Co., Ltd. (Nasdaq: LRE) (“LRE” or “the Company”), a Japanese real estate developer of luxury residential properties including single-family homes and condominiums across Tokyo, Kanagawa prefecture and Sapporo, today announced that it has entered into a business alliance agreement with Samurai Capital Co., Ltd. an ESG-conscious real estate investment company also based in Tokyo. As per the agreement, which was signed on May 30, 2024, a trust beneficiary interest purchase agreement totaling approximately 4.1 billion Japanese yen, or about US$26.1 million, was concluded. About Lead Real Estate Co., Ltd Lead Real Estate Co., Ltd is a Japanese developer of luxury residential properties, including single-family homes...

SARASOTA, Fla., June 25, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share. The closing of the public offering is expected to occur on or about June 26, 2024, subject to the satisfaction of customary closing conditions. The gross proceeds of the offering are anticipated to be approximately $1,100,000 million before deducting placement agent fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the offering to fund the continued development...

Intermodal Electrical Distribution UnitIntermodal Electrical Distribution UnitIntermodal Electrical Distribution Unit MIAMI, FL, June 25, 2024 (GLOBE NEWSWIRE) — Safe & Green Holdings Corp. (NASDAQ: SGBX) (“Safe & Green Holdings” or the “Company”), a leading developer, designer, and fabricator of modular structures, announced today that Safe & Green Holdings has received an expansion of an agreement to manufacture seven additional container based electrical distribution centers as part of a multi-unit order for a client serving the big box retailer market. These units are in addition to the four units which the Company has already begun production. A modular electrical distribution center offers a flexible and customizable solution for distributing electricity from a single source to multiple destinations....

Established in 1932, the London Clinic is the UK’s Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) — Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today they are extending their commercial agreement with the prestigious London Clinic in London, UK. The contract extension establishes a higher price point for Nociscan, engages The London Clinic to...

HOLMDEL, N.J., June 25, 2024 (GLOBE NEWSWIRE) — BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) software infrastructure featuring passwordless, phoneless and token-less Identity-Bound Biometrics (IBB) authentication solutions, today announces that Los Angeles LGBT Center with 17 locations and nearly 800 employees has selected its PortalGuard® platform for secure, streamlined desktop sign-in that meets regulatory and insurance compliance requirements. The most prominent LGBTQ+ organization in the world, the Center offers programs, services, and advocacy spanning four areas: Health, Social Services and Housing, Culture and Education, and Leadership. The newly implemented system marks a significant advancement for the Center, offering a highly scalable...